Trial of Amiloride in Type 2 Diabetes with Proteinuria.

ABSTRACT:

Introduction

Renal Na⁺ retention and extracellular fluid volume expansion are hallmarks of nephrotic syndrome, which occurs even in the absence of activation of hormones that stimulate renal Na⁺ transporters. Plasmin-dependent activation of the epithelial Na⁺ channel (ENaC) has been proposed to have a role in renal Na⁺ retention in the setting of nephrotic syndrome. We hypothesized that the ENaC inhibitor amiloride would be an effective therapeutic agent in inducing a natriuresis and lowering blood pressure in individuals with macroscopic proteinuria.

Methods

We conducted a pilot double-blind randomized cross-over study comparing the effects of daily administration of either oral amiloride or hydrochlorothiazide (HCTZ) to patients

SUBMITTER: Unruh ML 

PROVIDER: S-EPMC5584552 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature